PHIO - Phio Pharmaceuticals Corp.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Phio Pharmaceuticals Corp.

257 Simarano Drive
Suite 101
Marlborough, MA 01752
United States
508-767-3861
http://www.phiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Dr. Gerrit Dispersyn Ph.D., Dr. Med. ScPres & CEO368.81kN/A1975
Ms. Caitlin KontulisVP of Fin. & Admin. and Sec.N/AN/A1986
Dr. John A. BarrettChief Devel. OfficerN/AN/A1954
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Phio Pharmaceuticals Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.